Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 13
What the incretin review can tell us
A new narrative review maps incretin therapies across clinical care. Here is what that synthesis can clarify, and what it cannot decide.
Obesity care outside trials
A new review examines how access, tolerability, persistence, and support can shape anti-obesity treatment outcomes in routine care.
GLP-1 use before bariatric surgery
A matched retrospective study linked prior GLP-1RA or tirzepatide use to lower recorded early cardiorenal events after bariatric surgery.
What four months of semaglutide can show
A personal four-month timeline can document experience, but it cannot replace the controlled outcomes, safety data, or context of a semaglutide trial.
Why Semaglutide Treatment Plans Differ
Long-term semaglutide trials offer useful context, but a scale trend alone cannot determine an individual's treatment plan.
Semaglutide, weight loss and body image
Semaglutide trials measure weight and health outcomes. They cannot promise confidence, happiness, or a particular body-image result.
Tirzepatide Anaphylaxis and Skin Testing
A new case report links tirzepatide anaphylaxis with positive skin prick testing. Here is what one reported event can and cannot establish.
DUTCH-WAIST: semaglutide and heart rhythm
DUTCH-WAIST will test semaglutide-assisted weight loss alongside standard care after cardioversion. Its 2026 paper describes the design, not results.
GLP-1 Patient Experiences in Jeddah
A survey in three Jeddah hospitals recorded patient concerns about GLP-1 medicines, but its cross-sectional design cannot establish causation.
What drives GLP-1 prescriptions?
New evidence and Medicare policy helped drive Wegovy fills sharply higher. Prescription counts still leave major questions about access, adherence and outcomes.
GLP-1s, sleep apnea and oral health
A new review connects GLP-1 based sleep-apnea treatment with oral microbiome questions, but direct clinical evidence is still missing.
GLP-1 therapy and asthma outcomes
A matched US cohort linked GLP-1-based therapy with fewer recorded asthma events in obesity. The design cannot prove that the medicines caused the difference.